RET comprehensive analysis
RET comprehensive analysis-994
Hereditary Cancer testing
Inherited Cancer testing
Multiple Endocrine Neoplasia, type 2
MEN2
This assay is intended for patients with a history consistent with Multiple Endocrine Neoplasia, type 2.
Immediately after collection, mix tube thoroughly by gentle inversion, 8 - 10 times, to prevent clotting
Lavender (EDTA), 10mL
Yellow ACD (A or B)
Immediately after collection, mix tube thoroughly by gentle inversion, 8 - 10 times, to prevent clotting
Yellow ACD (A or B)
LabCorp Clinical Questionnaire for Hereditary Cancer
Molecular Medicare Billing Request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.
Ambient (preferred) – 60 days
Refrigerated – 60 days
Frozen - NO
DNA - 8 weeks
- Frozen specimen
- Leaking tube
- Clotted specimen
- Hemolysis
- Quantity not sufficient for analysis (QNS)
- Incorrect anticoagulant
The coding region and flanking splice sites are analyzed by NGS (+/-10bp) and deletion/duplication analysis. Exon-level deletions/duplications are assessed by aCGH. Clinically significant findings are confirmed by Sanger sequencing or qPCR. Results are reported using ACMG guidelines and nomenclature recommended by the Human Genome Variation Society (HGVS).
An interpretive report will be included
81479
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.